<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="638">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05152849</url>
  </required_header>
  <id_info>
    <org_study_id>AXA1125-201</org_study_id>
    <nct_id>NCT05152849</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, Tolerability of AXA1125 in Fatigue Predominant PASC</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of AXA1125 in Subjects With Fatigue-Predominant Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axcella Health, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axcella Health, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the effects of AXA1125, an orally active mixture of amino acids,&#xD;
      compared to placebo, on improving muscle function (metabolism) following moderate exercise in&#xD;
      subjects with fatigue-Predominant Post-Acute Sequelae of SARS-CoV-2 as well as the safety and&#xD;
      tolerability of AXA1125. Subjects will take one dose of AXA1125 or a placebo twice daily for&#xD;
      28 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline at Week 4 in the phosphocreatine (PCr) recovery rate following moderate exercise, as assessed by 31P-magnetic resonance spectroscopy (MRS)</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PCr recovery rate as assessed by phosphorus magnetic resonance spectroscopy (31P-MRS)</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with improvement in PCr recovery rate</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum lactate level after a 6-minute walk test</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with serum lactate level â‰¤3 mmol/L after a 6MWT</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a decrease in venous serum lactate level from baseline after a 6MWT</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in distance traveled during a 6MWT</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjects' fatigue score as assessed by Chalder Fatigue Questionnaire (CFQ)-11</measure>
    <time_frame>Baseline to14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjects' fatigue score as assessed by Chalder Fatigue Questionnaire (CFQ)-11 before and after a 6MWT</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an improvement in fatigue score as assessed by CFQ-11 before and after a 6MWT</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection</condition>
  <arm_group>
    <arm_group_label>AXA1125 33.9g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>33.9 g AXA1125 administered orally BID with or without food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo administered orally BID with or without food</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AXA1125</intervention_name>
    <description>AXA1125 administered BID with or without food</description>
    <arm_group_label>AXA1125 33.9g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo administered BID with or without food</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to participate in the study and provide written informed consent&#xD;
&#xD;
          -  Male and female adults aged &gt; 18 years and less than 65 years&#xD;
&#xD;
          -  Must have had clinically suspected COVID-19 and a positive antibody test or a&#xD;
             documented SARS-CoV-2 infection (a positive reverse transcription polymerase chain&#xD;
             reaction test) at least 12 weeks prior to Screening&#xD;
&#xD;
          -  Must have fatigue-predominant PASC&#xD;
&#xD;
          -  Other than PASC, a subject must be in good health without other significant medical or&#xD;
             not well controlled medical or psychiatric conditions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other than PASC, have an explanation for fatigue&#xD;
&#xD;
          -  Other than PASC, a history or presence of an uncontrolled, clinically significant&#xD;
             disease&#xD;
&#xD;
          -  Medical history that includes of Non-invasive or invasive ventilatory support for&#xD;
             COVID 19, Intensive care unit or other high dependency unit admission for COVID-19,&#xD;
             Hospitalization for &gt;1 week for COVID-19 without intubation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Betty Raman, MBBS DPhil FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford University Hospitals NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret Koziel</last_name>
    <phone>(857) 320-3200</phone>
    <email>clinicaltrials@axcellatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betty Raman, MBBS FRACP DPhil</last_name>
      <email>pasc@cardiov.ox.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Long COVID</keyword>
  <keyword>Long-haul COVID</keyword>
  <keyword>Muscle weakness</keyword>
  <keyword>COVID</keyword>
  <keyword>PASC</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Amino acids</keyword>
  <keyword>Bioenergetics</keyword>
  <keyword>Mitochondrial dysfunction</keyword>
  <keyword>Phosphocreatine recovery</keyword>
  <keyword>Exertional fatigue</keyword>
  <keyword>Phospho magnetic resonance spectroscopy</keyword>
  <keyword>Skeletal muscle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

